Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-100
SponsorShen Chun-Hong

About this trial

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.

It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

Eligibility criteria

Qualifiers

Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months

Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics

There is no obvious suspicion of autoimmune encephalitis

Written informed consent and sera are obtained

Disqualifiers

Patients have other etiology of seizures, such as structure, infection, genetics and metabolism.

Written informed consent are not obtained

Loss of follow-up

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Shen Chun-Hong

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor institution